HC Wainwright reissued their buy rating on shares of BioCardia (NASDAQ:BCDA – Free Report) in a report issued on Monday morning, Benzinga reports. The brokerage currently has a $25.00 target price on the stock.
BioCardia Stock Performance
Shares of BCDA opened at $2.63 on Monday. The company has a 50-day simple moving average of $2.72 and a 200-day simple moving average of $3.62. BioCardia has a 52 week low of $1.96 and a 52 week high of $23.25. The firm has a market capitalization of $5.58 million, a P/E ratio of -0.49 and a beta of 1.26.
BioCardia (NASDAQ:BCDA – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.78). As a group, equities analysts forecast that BioCardia will post -5.06 earnings per share for the current year.
About BioCardia
BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Recommended Stories
- Five stocks we like better than BioCardia
- 3 Small Caps With Big Return Potential
- Inflation Risk Rising, Key Trades Investors Are Making Now
- What Are Dividend Contenders? Investing in Dividend Contenders
- 3 Oil Stocks to Watch Before Earnings Come Out
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Is American Express Stock’s Sell-the-News Reaction a Buying Opp?
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.
